Across TCGA pan-cancer cohorts, EFCAB7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EFCAB7 data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EFCAB7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EFCAB7 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where EFCAB7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.352	0.639	.001	49	view →
LUAD	OS	Tertile	II,III,IV	0.854	0.385	<.001	27	view →
CCRCC	OS	Tertile	III,IV	1.000	0.770	.030	11	view →
LSCC	DFS	Median	II,III,IV	0.818	0.999	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: EFCAB7 tumor-vs-normal RNA expression · all EFCAB7 data types